Search results for "OSTEONECROSIS"

showing 10 items of 187 documents

Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - Review.

2015

Background Denosumab, an anti-resorptive agent, IgG2 monoclonal antibody for human Receptor activator of nuclear factor-kappa B ligand (RANKL), has been related to the occurrence of osteonecrosis of the jaws. Thus, the aim of this study was to review the literature from clinical case reports, regarding the type of patient and the therapeutic approach used for osteonecrosis of the jaws induced by chronic use of Denosumab. Material and Methods For this, a literature review was performed on PubMed, Medline and Cochrane databases, using the keywords “Denosumab” “anti-RANK ligand” and “Osteonecrosis of jaw”. To be included, articles should be a report or a serie of clinical cases, describing pat…

OncologyMalemedicine.medical_specialtyOsteoporosisOdontologíaReview03 medical and health sciencesTherapeutic approachProstate cancer0302 clinical medicineDiabetes mellitusInternal medicinemedicineHumansGeneral DentistryAgedBisphosphonate-associated osteonecrosis of the jawOral Medicine and PathologybiologyBone Density Conservation AgentsDiphosphonatesbusiness.industryRANK LigandNF-kappa BOsteonecrosis030206 dentistryMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludSurgeryDenosumabOtorhinolaryngologyRANKL030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASbiology.proteinSurgeryBisphosphonate-Associated Osteonecrosis of the JawFemaleDenosumabbusinessOsteonecrosis of the jawmedicine.drugMedicina oral, patologia oral y cirugia bucal
researchProduct

Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib.

2018

Medication-related osteonecrosis of the jaw (MRONJ) is an adverse drug reaction that affects the mandible and maxilla of patients exposed to bone-targeting agents such as anti-resorptive and anti-angiogenic agents. Several MRONJ cases have been reported after dental extractions in patients under treatment with anti-angiogenic agents, including receptor activator of nuclear factor κB ligand (RANKL) inhibitor, anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibody, mammalian target of rapamycin (mTOR) inhibitors, and tyrosine kinase inhibitors (TKIs). The aim of this article was to describe an original case of lenvatinib-related osteonecrosis of the jaw in a patient affected …

OncologyMalemedicine.medical_specialtymedicine.medical_treatmentlenvatinibMRONJ03 medical and health scienceschemistry.chemical_compound0302 clinical medicineSettore MED/28 - Malattie OdontostomatologicheInternal medicinemedicineAnimalsHumansThyroid cancerbiologyBone Density Conservation AgentsDiphosphonatesbusiness.industryPhenylurea CompoundsOsteonecrosis030206 dentistryMiddle Agedmedicine.diseaseosteonecrosis of the jawOtorhinolaryngologyDental extractionchemistryRANKL030220 oncology & carcinogenesisConcomitantbiology.proteinQuinolinesSurgeryBisphosphonate-Associated Osteonecrosis of the Jawdental extractionOral SurgerybusinessLenvatinibOsteonecrosis of the jawTyrosine kinaseAdverse drug reactionInternational journal of oral and maxillofacial surgery
researchProduct

Maxillary osteonecrosis associated to antiangiogenic drugs.

2009

Oncologymedicine.medical_specialtyBevacizumabbusiness.industryMEDLINEOsteonecrosisAntibodies MonoclonalAngiogenesis Inhibitors:CIENCIAS MÉDICAS [UNESCO]Antibodies Monoclonal HumanizedMaxillary DiseasesBevacizumabText miningOtorhinolaryngologyInternal medicineUNESCO::CIENCIAS MÉDICASMonoclonalMedicineHumansSurgerybusinessGeneral Dentistrymedicine.drugMedicina oral, patologia oral y cirugia bucal
researchProduct

Osteonecrosis of the jaw (ONJ) risk in breast cancer patients after zoledronic acid treatment

2010

The importance of adoption of recommendations for ONJ prevention strategy will notably grow for zoledronic acid in the next future, in view of possible further enlargement of its indications (even with different timing and schedules) in breast cancer patients without bone metastases (such as in adjuvant and neo-adjuvant settings, and in hormonotherapy-induced osteopenia

Oncologymedicine.medical_specialtyBreast Neoplasmszoledronic acidBreast cancerSettore MED/28 - Malattie OdontostomatologicheInternal medicinemedicineHumansBone Density Conservation AgentsDiphosphonatesOsteonecrosis of the jawbusiness.industryImidazolesOsteonecrosisGeneral Medicinemedicine.diseaseosteonecrosis jawsZoledronic acidJawbreast cancer patientsFemaleSurgerybusinessOsteonecrosis of the jawmedicine.drugThe Breast
researchProduct

Review of: "OSTEONECROSIS OF THE JAW (ONJ) IN BREAST CANCER PATIENTS: EFFECT OF PREVENTIVE MEASURES IN A MONOINSTITUTIONAL EXPERIENCE"

2021

Oncologymedicine.medical_specialtyBreast cancerbusiness.industryInternal medicineGeneral Engineeringmedicinemedicine.diseaseOsteonecrosis of the jawbusinessQeios
researchProduct

Biomarkers to predict the onset of biphosphonate-related osteonecrosis of the jaw: A systematic review

2019

Background: The goal of this paper was to identify available biomarkers to predict the onset of biphosphonate-related osteonecrosis of the jaw (BRONJ). Material and Methods: Case-control studies comparing the different concentrations of a series of molecules detected in serum and urine as matrices of BRONJ affected patients vs. non-affected were included. PRISMA guidelines for systematic reviews were used for the present paper. Two reviewers independently screened electronic databases (Medline, Web of science, and The Cochrane Library) and performed hand searches. Risk of bias assessment of selected studies was performed by the Newcastle-Ottawa Scale. This study is registered as PROSPERO CR…

Oncologymedicine.medical_specialtyMEDLINEReviewCochrane LibraryRisk Assessment03 medical and health sciences0302 clinical medicineBiphosphonatePredictive Value of TestsInternal medicinemedicineHumansGeneral DentistryOral Medicine and PathologyBisphosphonate-associated osteonecrosis of the jawbusiness.industryCase-control study030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]Systematic reviewOtorhinolaryngologyCase-Control Studies030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASBisphosphonate-Associated Osteonecrosis of the JawSurgerybusinessRisk assessmentOsteonecrosis of the jawBiomarkers
researchProduct

Osteonecrosis of the jaws produced by sunitinib : a systematic review

2019

Background Tyrosine kinase receptor family is involved in tumor growth, pathological angiogenesis and the progression (metastasis) of cancer. Sunitinib (Sutent®) inhibits members of the tyrosine kinase receptor family affecting the induction of angiogenesis and tumor progression. It is not clear if sunitinib increases the risk of osteonecrosis of the jaws (ONJ). The aim of this study was to carry out a systematic review about ONJ related to sunitinib, describing existing cases and possible associated risk factors. Material and Methods The PubMed/MEDLINE and Cochrane Library databases were searched without date restriction up to September 2018. We included prospective and retrospective obser…

Oncologymedicine.medical_specialtyPopulationMEDLINEReviewCochrane Library03 medical and health sciences0302 clinical medicineInternal medicineSunitinibmedicineHumansProspective StudieseducationProspective cohort studyGeneral DentistryRetrospective Studieseducation.field_of_studyOral Medicine and PathologyBone Density Conservation AgentsDiphosphonatesSunitinibbusiness.industryOsteonecrosisRetrospective cohort study030206 dentistry:CIENCIAS MÉDICAS [UNESCO]Cross-Sectional StudiesDenosumabOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryObservational studybusinessmedicine.drug
researchProduct

Definition and estimation of osteonecrosis of jaw (ONJ), and optimal duration of antiresorptive treatment in bone metastatic cancer patients: supplem…

2017

To the Editor, In their recent article, Stopeck et al. [1] concluded that denosumab confirms its known safety profile even after longterm exposure, or after switching to it from zoledronic acid, and that osteonecrosis of jaws (ONJ) rates increased with increasing exposure to antiresorptives, consistent with previous reports. This is based on the open label extension phase of two phase 3 studies in patients with breast and prostate cancer with bone metastases who were randomized to receive denosumab or zoledronic acid (ZA) [2, 3]. The patients were offered open-label denosumab for up to an additional 2 years after the results of the primary analysis, favorable for denosumab on several aspect…

Oncologymedicine.medical_specialtyPopulationlaw.invention03 medical and health sciencesProstate cancer0302 clinical medicineBreast cancerRandomized controlled triallawInternal medicineNeoplasmsmedicineHumanseducationLetter to the Editoreducation.field_of_studyBisphosphonate-associated osteonecrosis of the jawBone Density Conservation AgentsDiphosphonatesbusiness.industryOsteonecrosisCancer030206 dentistrymedicine.diseaseSurgeryDenosumabZoledronic acidOncology030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawDenosumabOncology osteonecrosis denosumab metastatic cancer patientsbusinessJaw Diseasesmedicine.drug
researchProduct

Advantages and Disadvantages of Bone Protective Agents in Metastatic Prostate Cancer: Lessons Learned

2016

Nine out of ten metastatic prostate cancer (PCa) patients will develop osseous metastases. Of these, every second will suffer from skeletal-related events (SRE). SRE are associated with an increased risk for death, which is markedly increased in the presence of pathological fracture. Moreover, health insurance costs nearly double in the presence of SRE. Zoledronic acid and denosumab are both approved drugs for the prevention or delay of SRE in castration-resistant prostate cancer (CRPC) patients with osseous metastases. However, long-term treatment with one of these two drugs is associated with the development of medication-related osteonecrosis of the jaw (MRONJ). Routine inspections of th…

Oncologymedicine.medical_specialtyReview03 medical and health sciencesProstate cancerzoledronic acid0302 clinical medicineInternal medicinemedicineStage (cooking)General DentistryPathologicalmedicine.diagnostic_testbusiness.industryIncidence (epidemiology)osteonecrosisdenosumab030206 dentistrymedicine.diseaseprostate cancerSurgerylcsh:RK1-715Zoledronic acidDenosumabBone scintigraphy030220 oncology & carcinogenesislcsh:DentistrybusinessOsteonecrosis of the jawmedicine.drugDentistry Journal
researchProduct

Simplifying the dental/periodontal management of patients with metabolic bone fragility receiving treatment with denosumab

2020

Denosumab (DNB) is a bone-targeted medication used to preserve structural integrity and minimise the risk of fragility fractures in metastatic cancer and metabolic bone disorders. DNB targets and binds RANK Ligand, inhibiting osteoclast maturation, function, and survival. In contrast with nitrogen-containing bisphosphonates (N-BPs), DNB does not bind to hydroxyapatite and incorporate into bone; thus, bone cellular remodelling recovers rapidly after drug suspension. Denosumab has benn linked to the occurrence of osteonecrosis of the jaw (MRONJ), a uncommon but severe oral side effect with a higher prevalence in metastatic cancer patients than in patients with metabolic bone fragility. Althou…

Oncologymedicine.medical_specialtySide effectbusiness.industrymedicine.medical_treatmentosteonecrosis of the jawsCancerdental managementdenosumabmedicine.diseaseMetabolic Bone DisorderOsteoclast maturationDenosumabdental management denosumab osteonecrosis of the jawsInternal medicineMedicineDosingbusinessOsteonecrosis of the jawReduction (orthopedic surgery)medicine.drug
researchProduct